SCHEMBL3850428

SCHEMBL3850428

CCOC(=O)c1c(O)c(C(C)C)nn(Cc2ccccc2Cl)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
LMNA P02545 4/20 0.47
MAPT P10636 3/20 0.47
GAA P10253 2/20 0.47
TSHR P16473 4/20 0.45
KDM4E B2RXH2 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
S1PR4 O95977 1/20 0.44
PDE4B Q07343 1/20 0.43
ALOX15 P16050 2/20 0.43
HPGD P15428 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TP53 P04637 1/20 0.42
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849126 0.92 ALDH1A1 (0.41) ALDH1A1LMNAMAPTGAATSHR
SCHEMBL3849080 0.88 PDE4B (0.42) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL3847540 0.88 ALDH1A1 (0.49) ALDH1A1LMNATSHRKDM4ESMN1; SMN2
SCHEMBL3853534 0.88 ALDH1A1 (0.47) ALDH1A1LMNATSHRKDM4ESMN1; SMN2
SCHEMBL3850324 0.88 KDM4E (0.44) ALDH1A1LMNAMAPTGAATSHR
SCHEMBL3849377 0.88 KDM4E (0.44) ALDH1A1LMNAGAAKDM4ESMN1; SMN2
SCHEMBL3853119 0.87 MAPK1 (0.55) ALDH1A1LMNAMAPTKDM4ESMN1; SMN2
SCHEMBL3850325 0.87 TSHR (0.47) ALDH1A1LMNAMAPTGAATSHR
SCHEMBL3849089 0.86 ALDH1A1 (0.53) ALDH1A1LMNAMAPTGAATSHR
SCHEMBL3857680 0.85 KDM4E (0.43) ALDH1A1LMNAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
CN-101626685-B N-substituted glycine derivatives: hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2013-03-13 CN disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN ALDH1A1 564/4885LMNA 2802/4885MAPT 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.